公开(公告)号：EP3049389A4

公开(公告)日：2017-04-19

申请号：EP14848555

申请日：2014-09-23

申请人： CHDI FOUNDATION INC

发明人： DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  WENT NAOMI

IPC分类号： C07D211/72 ,  A61K31/47 ,  A61P25/28 ,  C07D215/06 ,  C07D233/70 ,  C07D235/26 ,  C07D263/38 ,  C07D263/58 ,  C07D307/79

CPC分类号： C07D327/06 ,  C07D211/72 ,  C07D215/06 ,  C07D233/70 ,  C07D235/26 ,  C07D263/38 ,  C07D263/58 ,  C07D307/79 ,  C07D311/02 ,  C07D311/04 ,  C07D317/46 ,  C07D317/50 ,  C07D317/62 ,  C07D319/16 ,  C07D319/18

摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化合物或其药学上可接受的盐或前药。 还提供了药物组合物，其包含至少一种本文所述的化合物或其药学上可接受的盐或前药和一种或多种药学上可接受的载体。 描述了治疗患有对抑制KMO活性有响应的某些疾病和病症的患者的方法; 其包括给予这些患者一定量的至少一种有效降低疾病或病症的体征或症状的本文所述的化合物或其药学上可接受的盐或前药。 这些疾病包括神经退行性疾病，如亨廷顿病。 还描述了治疗方法，其包括施用本文所述的至少一种化合物或其药学上可接受的盐或前药作为单一活性剂或将至少一种本文所述的化合物或其药学上可接受的盐或前药与一种 更多其他治疗剂。 还提供了筛选能够抑制KMO活性的化合物的方法。

公开(公告)号：EP2751086A4

公开(公告)日：2015-09-16

申请号：EP12827656

申请日：2012-08-28

申请人： CHDI FOUNDATION INC

发明人： COURTNEY STEPHEN MARTIN ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  BROWN CHRISTOPHER JOHN ,  DE AGUIAR PENA PAULA C ,  JOHNSON PETER ,  DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  MUNOZ IGNACIO

IPC分类号： C07D239/47

CPC分类号： C07D239/28 ,  A61K31/506 ,  C07D239/42 ,  C07D239/52 ,  C07D401/04 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：EP2736337A4

公开(公告)日：2014-12-17

申请号：EP12817789

申请日：2012-07-26

申请人： CHDI FOUNDATION INC

发明人： DOMINIGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  COURTNEY STEPHEN MARTIN ,  PRIME MICHAEL ,  BROWN CHRISTOPHER JOHN ,  DE AGUIAR PENA PAULA C ,  JOHNSON PETER

IPC分类号： A01N43/54 ,  C07D239/42 ,  C07D471/04

CPC分类号： A61K31/506 ,  A61K31/505 ,  A61K31/513 ,  A61K31/5377 ,  C07D239/26 ,  C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D403/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D491/044 ,  C07D491/048 ,  C07D491/052

公开(公告)号：EP3049077A4

公开(公告)日：2017-02-15

申请号：EP14847911

申请日：2014-09-23

申请人： CHDI FOUNDATION INC

发明人： DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  WENT NAOMI

IPC分类号： A61K31/381 ,  A61P25/00 ,  C07D215/18 ,  C07D217/02 ,  C07D263/56 ,  C07D319/06 ,  C07D333/06 ,  C07D333/10

CPC分类号： C07D413/12 ,  C07D209/08 ,  C07D213/46 ,  C07D215/18 ,  C07D217/02 ,  C07D231/56 ,  C07D235/08 ,  C07D237/28 ,  C07D239/74 ,  C07D241/42 ,  C07D261/20 ,  C07D263/56 ,  C07D277/24 ,  C07D277/64 ,  C07D307/79 ,  C07D319/18 ,  C07D333/06 ,  C07D333/10 ,  C07D333/28 ,  C07D407/12

摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

公开(公告)号：EP2833879A4

公开(公告)日：2016-03-02

申请号：EP13772200

申请日：2013-03-13

申请人： CHDI FOUNDATION INC

发明人： TOLEDO-SHERMAN LETICIA M ,  DOMINGUEZ CELIA ,  PRIME MICHAEL ,  MITCHELL WILLIAM LEONARD ,  JOHNSON PETER ,  WENT NAOMI

IPC分类号： A61K31/19

CPC分类号： C07C62/38 ,  C07C69/757 ,  C07C229/22 ,  C07C229/46 ,  C07C229/48 ,  C07C235/82 ,  C07C317/44 ,  C07C323/62 ,  C07C2601/02 ,  C07C2602/50 ,  C07D203/08 ,  C07D203/10 ,  C07D207/08 ,  C07D207/337 ,  C07D215/18 ,  C07D233/64 ,  C07D235/26 ,  C07D257/04 ,  C07D263/58 ,  C07D271/07 ,  C07D295/155 ,  C07D305/06 ,  C07D305/08 ,  C07D307/54 ,  C07D307/79 ,  C07D307/80 ,  C07D307/94 ,  C07D309/10 ,  C07D311/58 ,  C07D317/46 ,  C07D317/60 ,  C07D319/18 ,  C07D403/10 ,  C07D405/08 ,  C07D405/10 ,  C07D405/12 ,  C07D413/08 ,  C07D413/10 ,  C07D413/12 ,  C07H15/20

公开(公告)号：EP2750677A4

公开(公告)日：2015-05-27

申请号：EP12828501

申请日：2012-08-28

申请人： CHDI FOUNDATION INC

发明人： COURTNEY STEPHEN MARTIN ,  PRIME MICHAEL ,  MITCHELL WILLIAM ,  BROWN CHRISTOPHER JOHN ,  DE AGUIAR PENA PAULA C ,  JOHNSON PETER ,  DOMINGUEZ CELIA ,  TOLEDO-SHERMAN LETICIA M ,  MUNOZ IGNACIO

IPC分类号： A61K31/44 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07H13/10

CPC分类号： C07D239/28 ,  C07D239/42 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D491/048 ,  C07D491/052 ,  C07H13/10

摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

摘要翻译： 本文提供了某些化学实体。 还提供了包含至少一种化学实体和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有某些对KMO活性抑制作用的疾病和病症的患者的方法，所述方法包括向所述患者施用一定量的至少一种有效减少疾病或病症的体征或症状的化学实​​体。 这些疾病包括神经变性疾病如亨廷顿舞蹈病。 还描述了治疗方法，包括给予至少一种作为单一活性剂的化学实体或与一种或多种其它治疗剂组合施用至少一种化学实体。 还提供了用于筛选能够抑制KMO活性的化合物的方法。